Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc.

NASDAQ:MRSN

Overview | Financials
Company Name Mersana Therapeutics, Inc.
Symbol MRSN
Currency USD
Price 1.84
Market Cap 225,722,000
Dividend Yield 0%
52-week-range 1.15 - 6.28
Industry Biotechnology
Sector Healthcare
CEO Dr. Martin H. Huber Jr., M.D.
Website https://www.mersana.com

An error occurred while fetching data.

About Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660,

Related Stocks

Aerovate Therapeutics, Inc. logo

Aerovate Therapeutics, Inc.

AVTE

2.72 USD

Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc.

CMPX

1.7 USD

Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

64.64 USD

Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc.

KZR

7.09 USD

InterCure Ltd. logo

InterCure Ltd.

INCR

1.06 USD

Icosavax, Inc. logo

Icosavax, Inc.

ICVX

15.31 USD

Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

ANIK

17.07 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

11.7 USD

Financials

Numbers are in millions USD

Numbers are in millions USD